INDIAN PHARMACOPOEIA COMMISSION  
National Coordination Centre - Pharmacovigilance Programme of India (PvPI)  
Ministry of Health & Family Welfare, Government of India

**ADRs Reporting Status, April 2019**

The spontaneous ADRs reporting by the ADR Monitoring Centres (AMCs) under Pharmacovigilance Programme of India (PvPI), Revised National Tuberculosis Control Programme (RNTCP) & Anti-Retroviral Therapy (ART) centres under National Health Programmes, and Pharmaceutical industries to National Coordination Centre-PvPI for the month of April-2019 has been compiled. During the April month of 2019 total **7711 ICSRs** were reported to NCC-PvPI. The detail is given below.

(I) Spontaneous ADRs reported by the AMCs, ART and RNTCP Centres as follows
No. of ICSRs received from AMC in the month of April 2019
No. of ICSRs recieved from AMC in the April 2019
No. of ICSRs recieved from AMC in the month of April 2019

<table>
<thead>
<tr>
<th>Name of AMCs</th>
<th>No. of ICSRs</th>
</tr>
</thead>
<tbody>
<tr>
<td>GMC-Srinagar</td>
<td>30</td>
</tr>
<tr>
<td>GMC-Trivandrum</td>
<td>28</td>
</tr>
<tr>
<td>GMC-Vadodara</td>
<td>11</td>
</tr>
<tr>
<td>GMC-Abhisekh</td>
<td>3</td>
</tr>
<tr>
<td>GMC-Tamladn</td>
<td>0</td>
</tr>
<tr>
<td>GSGC, Gorakhpur</td>
<td>9</td>
</tr>
<tr>
<td>GMC, Chennai</td>
<td>26</td>
</tr>
<tr>
<td>GSVN-Kanpur</td>
<td>25</td>
</tr>
<tr>
<td>HBTMC-Maharashtra</td>
<td>0</td>
</tr>
<tr>
<td>HIMR-New Delhi</td>
<td>0</td>
</tr>
<tr>
<td>HMC-Bhubaneswar</td>
<td>0</td>
</tr>
<tr>
<td>HTMC-Pasighat</td>
<td>12</td>
</tr>
<tr>
<td>ICAREIMS/R-Haldia</td>
<td>0</td>
</tr>
<tr>
<td>IGGM-Nagpur</td>
<td>20</td>
</tr>
<tr>
<td>IGIC-Bengaluru</td>
<td>44</td>
</tr>
<tr>
<td>IGMC-Nagpur</td>
<td>40</td>
</tr>
<tr>
<td>IGMS-Varanasi</td>
<td>35</td>
</tr>
<tr>
<td>IMA-HO-New Delhi</td>
<td>0</td>
</tr>
<tr>
<td>IBS-New Delhi</td>
<td>2</td>
</tr>
<tr>
<td>IMS-HU-Varanasi</td>
<td>2</td>
</tr>
<tr>
<td>IREDMS-Jaipur</td>
<td>60</td>
</tr>
<tr>
<td>IJS-FMSR-Tamnadra</td>
<td>0</td>
</tr>
<tr>
<td>IGMS-Shimla</td>
<td>37</td>
</tr>
<tr>
<td>IGMC-Patna</td>
<td>30</td>
</tr>
<tr>
<td>IGMCR-Parbhani</td>
<td>170</td>
</tr>
<tr>
<td>KAMSRC-Telangana</td>
<td>120</td>
</tr>
<tr>
<td>KCGMC-Haryana</td>
<td>3</td>
</tr>
<tr>
<td>KGMC-Mumbai</td>
<td>0</td>
</tr>
<tr>
<td>KGH-Vishakpathnam</td>
<td>10</td>
</tr>
<tr>
<td>KGRC-Kanyakumari</td>
<td>1</td>
</tr>
<tr>
<td>KIMS-Bhubaneswar</td>
<td>20</td>
</tr>
<tr>
<td>KIMS-Amalapuram</td>
<td>0</td>
</tr>
<tr>
<td>KMON-Hubli</td>
<td>0</td>
</tr>
<tr>
<td>JSS-Mysore</td>
<td>0</td>
</tr>
<tr>
<td>KMC-Aligarh</td>
<td>0</td>
</tr>
<tr>
<td>JJMSRC-Bihar</td>
<td>0</td>
</tr>
<tr>
<td>JNMC-Wardha</td>
<td>0</td>
</tr>
<tr>
<td>JIPMER-Kolkata</td>
<td>0</td>
</tr>
<tr>
<td>JMC-Jorhat</td>
<td>0</td>
</tr>
<tr>
<td>JNMC-Wardha</td>
<td>0</td>
</tr>
<tr>
<td>JSS-Mysore</td>
<td>0</td>
</tr>
<tr>
<td>KAMSRC-Telangana</td>
<td>0</td>
</tr>
<tr>
<td>KCGMC-Haryana</td>
<td>0</td>
</tr>
<tr>
<td>KGH-Vishakpathnam</td>
<td>10</td>
</tr>
<tr>
<td>KGRC-Kanyakumari</td>
<td>1</td>
</tr>
<tr>
<td>KIMS-Bhubaneswar</td>
<td>20</td>
</tr>
<tr>
<td>KIMS-Amalapuram</td>
<td>0</td>
</tr>
<tr>
<td>KMON-Hubli</td>
<td>0</td>
</tr>
</tbody>
</table>

Page 4 of 10
<table>
<thead>
<tr>
<th>Name of AMCs</th>
<th>No. of ICSRs received in April 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSCBMC-Jabalpur</td>
<td>12</td>
</tr>
<tr>
<td>NSMC-Kolkata</td>
<td>17</td>
</tr>
<tr>
<td>OMC-Imphal</td>
<td>19</td>
</tr>
<tr>
<td>PDUMC-Rajkot</td>
<td>0</td>
</tr>
<tr>
<td>PESIMSR-Chandigarh</td>
<td>30</td>
</tr>
<tr>
<td>PGIMSR-Pondicherry</td>
<td>18</td>
</tr>
<tr>
<td>PMS-Pondicherry</td>
<td>18</td>
</tr>
<tr>
<td>PMC-Jharkhand</td>
<td>16</td>
</tr>
<tr>
<td>PMCSKH-Anand</td>
<td>0</td>
</tr>
<tr>
<td>PS-Gujarat</td>
<td>1</td>
</tr>
<tr>
<td>RDGMC-Ujjain</td>
<td>0</td>
</tr>
<tr>
<td>RGMC-Kolkota</td>
<td>10</td>
</tr>
<tr>
<td>RIMS-Etawah</td>
<td>1</td>
</tr>
<tr>
<td>RIMS-Impenal</td>
<td>34</td>
</tr>
<tr>
<td>RIMS-Kolkata</td>
<td>50</td>
</tr>
<tr>
<td>RIMS-Lucknow</td>
<td>48</td>
</tr>
<tr>
<td>RNTMC-Udaipur</td>
<td>38</td>
</tr>
<tr>
<td>SAIMS-Indore</td>
<td>28</td>
</tr>
<tr>
<td>SBKSMI/RC-Wagholi</td>
<td>62</td>
</tr>
<tr>
<td>SBGMC-Cuttack</td>
<td>48</td>
</tr>
<tr>
<td>SCMC-Dharwad</td>
<td>17</td>
</tr>
<tr>
<td>SDJRC-Bangalore</td>
<td>17</td>
</tr>
<tr>
<td>SDU-Kolar</td>
<td>9</td>
</tr>
<tr>
<td>SDU-Trivandrum</td>
<td>8</td>
</tr>
<tr>
<td>SGMC/g-Lucknow</td>
<td>38</td>
</tr>
<tr>
<td>SGMC/g-Lucknow</td>
<td>30</td>
</tr>
<tr>
<td>SGMC/R-Dehradun</td>
<td>16</td>
</tr>
<tr>
<td>SHH-Kolar</td>
<td>16</td>
</tr>
<tr>
<td>SIMS-Cuttack</td>
<td>21</td>
</tr>
<tr>
<td>SIMS-Sriharim</td>
<td>0</td>
</tr>
<tr>
<td>SIMS-Sriharim</td>
<td>0</td>
</tr>
<tr>
<td>SIMS-Lucknow</td>
<td>0</td>
</tr>
<tr>
<td>SIMS-Lucknow</td>
<td>0</td>
</tr>
<tr>
<td>SIMS-Trivandrum</td>
<td>0</td>
</tr>
<tr>
<td>SIMS-Lucknow</td>
<td>0</td>
</tr>
</tbody>
</table>

No. of ICSRs received from AMC in the month of April 2019
No. of ICSRs received from ART and RNTCP in the month of April 2019

Name of AMCs

No. of ICSRs
(II) Spontaneous ADRs reported by the Pharmaceutical Industries as follows:

<table>
<thead>
<tr>
<th>S.No.</th>
<th>Industry Name</th>
<th>No. of ICSRs</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Abbott India Limited</td>
<td>12</td>
</tr>
<tr>
<td>2</td>
<td>Akums Drugs &amp; Pharmaceuticals Limited</td>
<td>8</td>
</tr>
<tr>
<td>3</td>
<td>Allergan India Pvt. Ltd.</td>
<td>22</td>
</tr>
<tr>
<td>4</td>
<td>Astellas Pharma India Private Limited</td>
<td>25</td>
</tr>
<tr>
<td>5</td>
<td>Aurobindo Pharma Limited</td>
<td>32</td>
</tr>
<tr>
<td>6</td>
<td>Amgen India</td>
<td>9</td>
</tr>
<tr>
<td>7</td>
<td>Baxalta</td>
<td>3</td>
</tr>
<tr>
<td>8</td>
<td>Baxter (India) Private Limited</td>
<td>298</td>
</tr>
<tr>
<td>9</td>
<td>Bayer Healthcare Limited</td>
<td>36</td>
</tr>
<tr>
<td>10</td>
<td>Bharat biotech</td>
<td>1</td>
</tr>
<tr>
<td>11</td>
<td>Biocon Limited</td>
<td>45</td>
</tr>
<tr>
<td>12</td>
<td>Boehringer Ingelheim India Private Limited</td>
<td>43</td>
</tr>
<tr>
<td>13</td>
<td>Bristol-Myers Squibb India</td>
<td>48</td>
</tr>
<tr>
<td>14</td>
<td>Bharat Serums And Vaccines Limited</td>
<td>1</td>
</tr>
<tr>
<td>15</td>
<td>Cadila</td>
<td>3</td>
</tr>
<tr>
<td>16</td>
<td>Cipla Limited</td>
<td>39</td>
</tr>
<tr>
<td>17</td>
<td>Dr.Reddy’s Laboratories</td>
<td>15</td>
</tr>
<tr>
<td>18</td>
<td>Eisai Pharmaceuticals India Pvt. Ltd</td>
<td>150</td>
</tr>
<tr>
<td>19</td>
<td>Eli Lilly &amp; Company (India) Private Limited</td>
<td>110</td>
</tr>
<tr>
<td>20</td>
<td>Emcure Pharmaceuticals Limited</td>
<td>41</td>
</tr>
<tr>
<td>21</td>
<td>FDC</td>
<td>1</td>
</tr>
<tr>
<td>22</td>
<td>Fresenius Kabi India Private Limited</td>
<td>8</td>
</tr>
<tr>
<td>23</td>
<td>Glaxo Smithkline Pharmaceuticals Limited</td>
<td>21</td>
</tr>
<tr>
<td>24</td>
<td>Glenmark Pharmaceuticals</td>
<td>47</td>
</tr>
<tr>
<td>25</td>
<td>Hetero Drugs Limited</td>
<td>22</td>
</tr>
<tr>
<td>26</td>
<td>Intas Pharmaceuticals Limited (Lambda CRO)</td>
<td>7</td>
</tr>
<tr>
<td>27</td>
<td>IPCA Laboratories Limited</td>
<td>6</td>
</tr>
<tr>
<td>28</td>
<td>Johnsons &amp; Johnsons Private Limited</td>
<td>49</td>
</tr>
<tr>
<td>29</td>
<td>Lupin Limited</td>
<td>59</td>
</tr>
<tr>
<td>30</td>
<td>Lundbeck Pharmaceutical company</td>
<td>4</td>
</tr>
<tr>
<td>31</td>
<td>Macleods Pharmaceuticals Limited</td>
<td>8</td>
</tr>
<tr>
<td>32</td>
<td>MERCK Limited</td>
<td>90</td>
</tr>
<tr>
<td>33</td>
<td>MSD Pharmaceuticals Ltd.</td>
<td>170</td>
</tr>
<tr>
<td>34</td>
<td>MSN Labs</td>
<td>10</td>
</tr>
<tr>
<td>35</td>
<td>Mylan Laboratories Private Limited</td>
<td>12</td>
</tr>
<tr>
<td>36</td>
<td>Mankind Pharma (Lambda CRO)</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Company Name</td>
<td>Code</td>
</tr>
<tr>
<td>---</td>
<td>-------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>37</td>
<td>Novartis India Limited</td>
<td>897</td>
</tr>
<tr>
<td>38</td>
<td>Novo Nordisk India</td>
<td>2</td>
</tr>
<tr>
<td>39</td>
<td>Oviamedsafe</td>
<td>3</td>
</tr>
<tr>
<td>40</td>
<td>Pfizer Limited</td>
<td>360</td>
</tr>
<tr>
<td>41</td>
<td>Panacea Biotec Limited</td>
<td>5</td>
</tr>
<tr>
<td>42</td>
<td>Roche Products (India) Private Limited</td>
<td>134</td>
</tr>
<tr>
<td>43</td>
<td>Reliance Life Sciences</td>
<td>6</td>
</tr>
<tr>
<td>44</td>
<td>Reckitt Benkiser</td>
<td>4</td>
</tr>
<tr>
<td>45</td>
<td>Sanofi India Limited</td>
<td>280</td>
</tr>
<tr>
<td>46</td>
<td>Serdia Pharmaceuticals (India) Limited</td>
<td>1</td>
</tr>
<tr>
<td>47</td>
<td>Sun Pharmaceuticals Industries Limited</td>
<td>57</td>
</tr>
<tr>
<td>48</td>
<td>Serum Institute of India Limited. (Lambda CRO)</td>
<td>3</td>
</tr>
<tr>
<td>49</td>
<td>Torrent Pharmaceuticals Limited</td>
<td>57</td>
</tr>
<tr>
<td>50</td>
<td>UCB India Pvt. Limited</td>
<td>19</td>
</tr>
<tr>
<td>51</td>
<td>USV Private Limited</td>
<td>2</td>
</tr>
<tr>
<td>52</td>
<td>Vifor Pharma</td>
<td>2</td>
</tr>
<tr>
<td>53</td>
<td>Wockhardt Pharmaceutical Limited</td>
<td>1</td>
</tr>
<tr>
<td>54</td>
<td>Zydus Cadila</td>
<td>50</td>
</tr>
<tr>
<td></td>
<td><strong>Total</strong></td>
<td><strong>3339</strong></td>
</tr>
</tbody>
</table>

**Acknowledgement** - NCC-PvPI acknowledges all the stakeholders for their contribution.